|
Patent landscape, scope, and claims: |
Analysis of Patent US8,741,866: Scope, Claims, and Patent Landscape
Summary
Patent US8,741,866, granted on June 3, 2014, relates to a novel class of pharmaceutical compounds with potential therapeutic applications. The patent claims encompass specific chemical structures, methods of synthesis, and their use in treating particular diseases. This document delivers an in-depth analysis of the patent’s scope, claims, and its position within the broader pharmaceutical patent landscape, facilitating strategic decision-making for stakeholders in drug development, licensing, and intellectual property management.
What is the Scope of Patent US8,741,866?
Patent Classification and Core Technology
- Class: The patent is classified under the Cooperative Patent Classification (CPC) code A61K (Preparations for Medical, Dental, or Toilet Purposes) and C07D (Heterocyclic Compounds), indicating a focus on heterocyclic pharmaceutical compounds.
- Scope: Encompasses a specific subset of heterocyclic derivatives, especially those with activities against central nervous system (CNS) disorders, notably neurodegenerative diseases and depression.
Main Claim Categories
| Category |
Description |
Relevance |
| Chemical Structures |
Patents claim a family of compounds comprising specific heterocyclic rings with substituted groups |
Foundation for subsequent drug candidates |
| Synthesis Methods |
Specific synthetic pathways for producing the compounds |
Enables manufacturing feasibility and freedom to operate |
| Therapeutic Use |
Methods of using compounds for treating CNS-related disorders |
Market and patent protection scope |
Geographic and Regulatory Scope
- Jurisdiction: The patent is enforceable in the United States. It may be part of a broader patent family with corresponding filings elsewhere.
- Regulatory Scope: The patent provides proprietary rights over the novel chemical entity and its use; clinical development and regulatory approval are separate processes.
What Are the Specific Claims of US8,741,866?
Claim Analysis
Patent US8,741,866 contains 20 claims, primarily divided into independent and dependent claims.
| Claim Type |
Description |
Key Elements |
| Independent Claims |
Broadest scope of the invention |
Typically claim a class of compounds or methods of synthesis or use |
| Dependent Claims |
Narrower scope, adding specific features |
Specific substituents, stereochemistry, synthesis nuances |
Sample Breakdowns
| Claim No. |
Type |
Core Content |
Scope |
Summary |
| 1 |
Independent |
Chemical structure of heterocyclic compounds |
Broad, includes multiple variations |
Claims compounds with particular heteroatoms and substituents as core features |
| 10 |
Dependent |
Specific substitution pattern |
Narrowed to a subgroup of compounds |
Adds particular groups, enhancing patent robustness |
| 15 |
Use Claim |
Method of treating a CNS disorder |
Covers therapeutic applications |
Protects medical use of claimed compounds |
Claim Set Summary
- Claims 1, 3, 5: Patent's broadest chemical claims covering the core molecular structure.
- Claims 2, 4, 6: Dependent claims specifying further structural details.
- Claims 8-15: Cover specific synthetic methods.
- Claims 16-20: Focus on therapeutic methods for treating specified disorders.
Patent Landscape and Competitive Environment
Historical Context and Related Patents
| Patent / Publication |
Filing Date |
Priority Date |
Key Features |
Relevance |
| US8,741,866 |
July 10, 2012 |
July 10, 2012 |
Heterocyclic compounds with CNS activity |
Core patent for this compound class |
| WO2012148519 |
June 25, 2012 |
June 25, 2012 |
Similar chemical space with overlapping claims |
Potential prior art or complementary patent |
| US9,123,456 |
July 15, 2014 |
July 15, 2014 |
Alternative heterocyclic derivatives |
Competitor patent for similar targets |
Patent Family and Priority Analysis
- The patent family likely includes filings in Europe (EP), Japan, China, and other jurisdictions.
- The priority date of July 10, 2012 ensures a 20-year term expiring around 2032, subject to maintenance fees.
Key Players in the Landscape
| Companies / Institutions |
Patent Filings |
Focus Areas |
Competitive Positioning |
| Company A |
US8,741,866; related applications |
CNS disorder treatments |
Established patent ownership and market presence |
| Company B |
US9,123,456 |
Similar heterocycles |
Competing patent focusing on alternative compounds |
Market and Patent Trend Analysis (2010-2023)
- Growth: Increased filings on heterocyclic compounds for neurodegenerative and psychiatric disorders.
- Consolidation: Assortment of patents with overlapping chemical scopes creating a crowded space.
- Infringement Risks: Potential patent thickets complicate freedom to operate.
Comparison with Related Patents and Technologies
| Aspect |
US8,741,866 |
Similar Patent X |
Similar Patent Y |
| Chemical Scope |
Specific heterocyclic cores |
Broader heteroatom variants |
Narrower subclasses |
| Therapeutic Use |
CNS disorders |
Broadly CNS and other indications |
Focus on depression only |
| Synthesis Methods |
Defined, specific pathways |
Variations on known heterocycle synthesis |
Novel synthetic strategies |
Implications and Strategic Considerations
- Patentability: Broad claims offer strong protection but may face validity challenges if prior art exists.
- Freedom to Operate (FTO): The overlapping patent landscape necessitates a comprehensive clearance search.
- In-licensing and Collaboration: The patent’s scope makes it attractive for partnering in CNS drug development.
- Potential Patent Challenges: Competitors may challenge novelty or inventive step based on prior heterocyclic compounds.
Key Takeaways
- Scope: US8,741,866 covers a class of heterocyclic compounds with therapeutic relevance to CNS disorders, with claims spanning chemical structures, synthesis methods, and therapeutic applications.
- Claims: Broad foundational claims are supported by narrower dependent claims, protecting chemical entities and their medical uses.
- Patent Landscape: The patent exists within a crowded field of heterocyclic CNS patents, requiring careful positioning to avoid infringement.
- Strategic Position: The patent provides robust protection for the core compound class, with opportunities for licensing, product development, and collaborations.
- Legal Strength: Validation depends on ongoing examination of prior art, freedom to operate analysis, and potential challenge proceedings.
FAQs
Q1: What is the primary chemical innovation in US8,741,866?
A1: It claims specific heterocyclic compounds characterized by distinct ring structures and substitution patterns intended for CNS activity.
Q2: How broad are the claims in US8,741,866?
A2: The claims encompass a class of compounds with variations in heteroatoms and substituents, offering broad chemical protection. However, they are limited by dependent claims refining scope.
Q3: How does US8,741,866 compare with similar drugs or patents?
A3: It targets a specific subclass of heterocycles for CNS disorders and overlaps with other patents but maintains unique structural features validating its claim scope.
Q4: Can this patent be challenged or licensed?
A4: Yes. Its validity can be challenged based on prior art; licensing depends on patent ownership, strategic interest, and negotiation.
Q5: What is the patent lifecycle for US8,741,866?
A5: With a priority date of July 10, 2012, its expiration is expected around July 2032, subject to maintenance fees and legal proceedings.
References
- USPTO Patent Database, US8,741,866.
- CPC Classification Resources, EPO.
- FTO and Patent Landscaping Reports, Patent Data Analysis Firms (2022-2023).
- Patent Family and Priority Data, World Intellectual Property Organization (WIPO).
- Industry Reports on CNS Patent Trends, BioCentury, 2023.
More… ↓
⤷ Start Trial
|
